These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38976148)

  • 1. Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice.
    Debourdeau E; Beylerian H; Nguyen V; Barthelmes D; Gillies M; Gabrielle PH; Vujosevic S; Otoole L; Puzo M; Creuzot-Garcher C; Wolff B; Daien V;
    Ophthalmol Ther; 2024 Sep; 13(9):2343-2355. PubMed ID: 38976148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
    Augsburger M; Sarra GM; Imesch P
    Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years' Real-World Clinical Outcomes.
    Horner F; Lip PL; Mohammed BR; Fusi-Rubiano W; Gokhale E; Mushtaq B; Chavan R
    Clin Ophthalmol; 2021; 15():1703-1713. PubMed ID: 33935487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
    Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
    Hatz K; Prünte C
    Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To investigate treat and extend versus pro re nata regimen in neovascular age-related macular degeneration: results from the IDEM study.
    Faudi E; Gauthier AS; Delbosc B; Saleh M
    Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2149-2156. PubMed ID: 35020019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
    Lee AY; Lee CS; Egan CA; Bailey C; Johnston RL; Natha S; Hamilton R; Khan R; Al-Husainy S; Brand C; Akerele T; Mckibbin M; Downey L; Tufail A
    Br J Ophthalmol; 2017 Dec; 101(12):1683-1688. PubMed ID: 28478396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis.
    Danyliv A; Glanville J; McCool R; Ferreira A; Skelly A; Jacob RP
    Adv Ther; 2017 Mar; 34(3):611-619. PubMed ID: 28188433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration.
    Aurell S; Sjövall K; Paul A; Morén Å; Granstam E
    Acta Ophthalmol; 2019 Aug; 97(5):519-524. PubMed ID: 30511374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study.
    López Gálvez MI; Arias Barquet L; S Figueroa M; García-Layana A; Ruiz Moreno JM;
    Acta Ophthalmol; 2020 Nov; 98(7):e820-e829. PubMed ID: 32190990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis.
    Rosenberg D; Deonarain DM; Gould J; Sothivannan A; Phillips MR; Sarohia GS; Sivaprasad S; Wykoff CC; Cheung CMG; Sarraf D; Bakri SJ; Chaudhary V
    Eye (Lond); 2023 Jan; 37(1):6-16. PubMed ID: 35396574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration.
    Jia H; Lu B; Yuan Y; Yuan F; Li L; Song Y; Rong A; Zhou M; Wang F; Sun X
    Front Med (Lausanne); 2022; 9():852519. PubMed ID: 35795633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L; Krohn J
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of treat-and-extend versus pro re nata regimens in the treatment of Neovascular Age Macular Degeneration: A Real World Comparison.
    Meira J; Carneiro J; Madeira C; Falcão M; Beato J; Correia S; Falcão-Reis F; Carneiro Â
    Arch Soc Esp Oftalmol (Engl Ed); 2020 Jun; 95(6):263-270. PubMed ID: 32370878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
    Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
    BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
    Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
    Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.